Coronavirus: 90% effective Pfizer vaccine – BioNTech



[ad_1]

The companies’ announcement claims that the coronavirus vaccine had no serious side effects

The candidate vaccine Pfizer – BioNTech against coronavirus is 90% effective, according to its manufacturers, far exceeding initial expectations. This arises, according to international media, from the first intermediate results, in large-scale trials, for the vaccine of the two companies, which tested in 43,500 people and 6 countries.

These data contribute more than optimism to the scientific community, since the Regulatory Authorities have stated that they would approve a vaccine that would be at least 50% effective and, according to the company’s announcement, there were no serious side effects.

“Today is a great day for science and humanity. “The first phase of the results of the trial phase 3 of the vaccine gives us indications that our preparation can prevent the appearance of Covid in the body,” said the Dr. Albert Bourla, CEO and President of Pfizer.

“We are approaching this critical milestone in our vaccine development program, at a time when people need it more than ever, with record-breaking infection rates, hospitals reaching their limits and economies struggling to reopen.” he added. At the same time, the Ugur Sahin, one of the founders of BioNTech, described the development as “reference point».

According to the plan of the two companies, they will archive request for emergency approval of preparation at the end of November. The goal is to have enough doses by the end of the year to provide immunity for 15 to 20 million people, according to Pfizer executives.

With information from The Guardian, BBC, The New York Times

[ad_2]